RecruitingNCT07285096

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Efficacy and Safety of P-CABs-Based Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication: A Multicenter Cohort Study

Sponsor

Yueyue Li

Enrollment

1,730 participants

Start Date

Dec 16, 2025

Study Type

OBSERVATIONAL

Conditions

Helicobacter Pylori Infection

Summary

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria3

patients aged 18-70 years, regardless of gender;
willing to receive H. pylori eradication therapy;
diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.

Exclusion Criteria2

patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;
patients who received treatment regimens that did not comply with the quadruple regimens specified in this study.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDoctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstances，not involve any intervention procedures

Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstances，not involve any intervention procedures.